{
    "body": "Is EZH2 associated with prostate cancer?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21941025", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24375374", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23739676", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17134822", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16330673", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22505648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16015586", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16575874", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17914578", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17252556", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23636686", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18095286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25017995", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12374981", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18637271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21241820", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23286483", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15264237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18159594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25115397", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22805308"
    ], 
    "ideal_answer": [
        "EZH2 is an epigenetic driver of prostate cancer. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer. EZH2 plays an active role in this process by repressing the expression of TIMP2 and TIMP3 in prostate cancer cells. EZH2 knockdown markedly reduces the proteolytic activity of MMP-9, thereby decreasing the invasive activity of prostate cancer cells. Composite index of c-Myc, EZH2, and p27 can be valued as powerful prognosis parameter for intermediate-risk prostate cancer patients after the surgery, and postoperative adjuvant therapy can be adopted accordingly."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.uniprot.org/uniprot/EZH2_HUMAN", 
        "http://www.disease-ontology.org/api/metadata/DOID:10283", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011471", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011467", 
        "http://www.disease-ontology.org/api/metadata/DOID:10286", 
        "http://www.uniprot.org/uniprot/EZH2_MACFA"
    ], 
    "type": "yesno", 
    "id": "570908e3cf1c325851000012", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 104, 
            "text": "The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 326, 
            "offsetInEndSection": 440, 
            "text": "EZH2 plays an active role in this process by repressing the expression of TIMP2 and TIMP3 in prostate cancer cells", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 442, 
            "offsetInEndSection": 618, 
            "text": "The TIMP genes are derepressed by knockdown of EZH2 expression in human prostate cancer cells but repressed by overexpression of EZH2 in benign human prostate epithelial cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 714, 
            "offsetInEndSection": 802, 
            "text": "Overexpression of EZH2 confers an invasive phenotype on benign prostate epithelial cells", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 872, 
            "offsetInEndSection": 1004, 
            "text": "EZH2 knockdown markedly reduces the proteolytic activity of MMP-9, thereby decreasing the invasive activity of prostate cancer cells", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1034, 
            "offsetInEndSection": 1257, 
            "text": "he transcriptional repression of the TIMP genes by EZH2 may be a major mechanism to shift the MMPs/TIMPs balance in favor of MMP activity and thus to promote ECM degradation and subsequent invasion of prostate cancer cells.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272343", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 346, 
            "offsetInEndSection": 577, 
            "text": "Expression levels of the novel tumor and metastasis suppressor Raf-1 kinase inhibitor protein (RKIP) have been shown to correlate negatively with those of EZH2 in breast and prostate cell lines as well as in clinical cancer tissues", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505648", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 145, 
            "text": "Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505648", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 104, 
            "offsetInEndSection": 344, 
            "text": "Enhancer of zeste homolog 2 (EZH2), which encodes the histone methyltransferase component of the polycomb repressive complex 2 (PRC2), is overexpressed widely in breast and prostate cancers and epigenetically silences tumor suppressor genes", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505648", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 137, 
            "offsetInEndSection": 242, 
            "text": "However, the roles and underlying mechanisms of EZH2 in prostate cancer stem cells (PCSCs) remain unknown", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23739676", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 257, 
            "text": "c-Myc, EZH2 and p27 were defined to modulate the behavior of prostate cancer with pro-tumoral or anti-tumoral effects and had ability in predicting prostate cancer progression, but the research of their co-expression value of prognosis is rarely", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286483", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1875, 
            "offsetInEndSection": 2089, 
            "text": "Composite index of c-Myc, EZH2, and p27 can be valued as powerful prognosis parameter for intermediate-risk prostate cancer patients after the surgery, and postoperative adjuvant therapy can be adopted accordingly.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286483", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 46, 
            "text": "EZH2, an epigenetic driver of prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636686", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 206, 
            "text": "The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636686", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 583, 
            "offsetInEndSection": 649, 
            "text": "a comprehensive overview of EZH2 in the context of prostate cancer", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23636686", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 85, 
            "text": "EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115397", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 942, 
            "offsetInEndSection": 1066, 
            "text": "ChIP data on prostate cancer tissue specimens and cell lines suggested EZH2 occupancy and H3K27Me3 marks on the ID4 promoter", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115397", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1068, 
            "offsetInEndSection": 1334, 
            "text": "Collectively, our data indicate a PRC2 dependent mechanism in ID4 promoter silencing in prostate cancer through recruitment of EZH2 and a corresponding increase in H3K27Me3. Increased EZH2 but decreased ID4 expression in prostate cancer strongly supports this model.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115397", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 212, 
            "text": "The histone methyltransferase enhancer of zeste homolog 2 (EZH2) has recently attracted considerable attention because of its dysregulation in prostate cancer (PCa) and its important function in PCa development. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25017995", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 101, 
            "text": "Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25017995", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1052, 
            "offsetInEndSection": 1267, 
            "text": "Amounts of both EZH2 messenger RNA and EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12374981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1885, 
            "offsetInEndSection": 2161, 
            "text": "The data show that amplification of the EZH2 gene is rare in early prostate cancer, whereas a fraction of late-stage tumors contains the gene amplification leading to the overexpression of the gene, thus indicating the importance of EZH2 in the progression of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575874", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 353, 
            "offsetInEndSection": 575, 
            "text": "EZH2 expression in prostate cancer correlates with progression to hormone-refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17252556", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 582, 
            "offsetInEndSection": 819, 
            "text": "Although prior studies in prostate cancer have revealed a number of possible mechanisms of EZH2 upregulation, these changes cannot account for the overexpression EZH2 in many primary prostate cancers, nor in most cases of high grade PIN.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21941025", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 829, 
            "offsetInEndSection": 1021, 
            "text": "As a result, five EZH2 peptides recognized by IgG (EZH2 120-128, EZH2 165-174, EZH2 569-577, EZH2 665-674, and EZH2 699-708) were frequently detected in the plasma of prostate cancer patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17914578", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1256, 
            "offsetInEndSection": 1460, 
            "text": "Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12374981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1554, 
            "offsetInEndSection": 1764, 
            "text": "These results link two major pathways in prostate cancer by providing two additional and complementary Myc-regulated mechanisms by which EZH2 upregulation occurs and is enforced during prostatic carcinogenesis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21941025", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 143, 
            "offsetInEndSection": 209, 
            "text": "EZH2 promotes prostate cancer cell proliferation and invasiveness.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18095286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 70, 
            "text": "EZH2 promotes proliferation and invasiveness of prostate cancer cells.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17252556", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 77, 
            "text": "The Polycomb Group protein EZH2 is implicated in prostate cancer progression.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18095286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 78, 
            "text": "The polycomb group protein EZH2 is involved in progression of prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12374981", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 102, 
            "text": "Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16015586", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637271", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 114, 
            "text": "The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575874", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 132, 
            "text": "Enhancer of zeste homolog 2 (EZH2), a kind of transcriptional repressor, is reportedly over-expressed in metastatic prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18159594", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 461, 
            "offsetInEndSection": 629, 
            "text": "IgGs reactive to three EZH2 peptides (EZH2-243 to -252, EZH2-291 to -299, and EZH2-735 to -;742) were detected in the plasma of almost half of prostate cancer patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15264237", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 843, 
            "offsetInEndSection": 1058, 
            "text": "Amounts of both EZH2 messenger RNA and EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12374981", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 293, 
            "offsetInEndSection": 443, 
            "text": "Overexpression of EZH2 has been associated with the invasion and progression of malignant cancers, especially with the progression of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21241820", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 190, 
            "text": "Antigens overexpressed in metastatic prostate cancer are appropriate targets in anti-cancer immunotherapy, and one candidate is the polycomb group protein enhancer of zeste homolog 2 (EZH2).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15264237", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 673, 
            "offsetInEndSection": 900, 
            "text": " Cytoplasmic EZH2 is expressed at low levels in benign prostate epithelial cells and over-expressed in prostate cancer cells. Cytoplasmic EZH2 expression levels correlate with nuclear EZH2 expression in prostate cancer samples.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18095286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 53, 
            "offsetInEndSection": 132, 
            "text": "DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18637271", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1330, 
            "offsetInEndSection": 1483, 
            "text": "EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence in a training set of 103 patients (relative risk [RR] = 2.52,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1197, 
            "offsetInEndSection": 1329, 
            "text": "a positive EZH2:ECAD status) was the biomarker combination that was most strongly associated with the recurrence of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1317, 
            "offsetInEndSection": 1447, 
            "text": "PcG proteins EZH2, BMI1, and RING1 are associated with adverse pathologic features and clinical PSA recurrence of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17134822", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 781, 
            "offsetInEndSection": 909, 
            "text": "Immunohistochemistry results were evaluated in conjunction with clinical parameters associated with prostate cancer progression,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 180, 
            "text": "Elevation of the chromatin repression factor enhancer of zeste homolog (EZH2) is associated with progression and poor prognosis in several human cancers including prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22805308", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 119, 
            "offsetInEndSection": 278, 
            "text": "Various proteins (\u03b12-integrin, \u03b16-integrin, CD117, CD133, EZH2, OCT3/4) are associated with a prostate cancer stem cell phenotype in cell lines and xenografts.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24375374", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 89, 
            "offsetInEndSection": 233, 
            "text": "Increased expression of EZH2 has been associated previously with invasive growth and aggressive clinical behavior in prostate and breast cancer,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16330673", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1942, 
            "offsetInEndSection": 2123, 
            "text": "EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence after radical prostatectomy and may be useful in defining a cohort of high-risk patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 781, 
            "offsetInEndSection": 990, 
            "text": "Immunohistochemistry results were evaluated in conjunction with clinical parameters associated with prostate cancer progression, including tumor stage, Gleason score, and prostate-specific antigen (PSA) level.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 165, 
            "text": "EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16330673", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1103, 
            "offsetInEndSection": 1329, 
            "text": "Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD (i.e., a positive EZH2:ECAD status) was the biomarker combination that was most strongly associated with the recurrence of prostate cancer.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12734317", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 799, 
            "offsetInEndSection": 900, 
            "text": "Cytoplasmic EZH2 expression levels correlate with nuclear EZH2 expression in prostate cancer samples.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18095286", 
            "endSection": "abstract"
        }
    ]
}